Acquisition of Epicentre Gives Illumina Exclusive Access to Nextera Sample-Prep Method | GenomeWeb

By Julia Karow

Illumina's recent acquisition of molecular biology reagent provider Epicentre Biotechnologies provides the company with exclusive access to a library prep method that researchers have said offers great advantages for next-generation sequencing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.